| September 28th | 2020 1:00AM
Vaccine by Johnson & Johnson Would Be a Boom for Investors… And Chances Just Increased
On Friday, Johnson & Johnson (NYSE: JNJ) released early results from the Phase 1/2 a clinical trial for its COVID-19 vaccine. One dose appeared to produce a strong immune response in 99% of the participants. There were some mild side effects, such as fever, headache, and fatigue, but they resolved after a couple of days.
JNJ’s vaccine, called Ad26.COV2.